NCT01299571 - AVODART(Dutasteride) Post-marketing Surveillance(PMS) | Biotech Hunter

Enrollment

3,977

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions

Benign Prostatic HyperplasiaProstatic Hyperplasia

Interventions

DRUG

Dutasteride

Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.

Trial Locations (1)

110-749

GSK Investigational Site, Seoul